重组人血管内皮抑素联合NP方案对人乳腺癌裸鼠移植瘤作用的实验研究

程丽; 张幸平; 杨鸿捷; 周涛琪; 饶明月

doi:10.13406/j.cnki.cyxb.2011.05.018

您当前的位置：

首页 >

文章列表页 >

重组人血管内皮抑素联合NP方案对人乳腺癌裸鼠移植瘤作用的实验研究

恶性肿瘤的诊断与治疗 | 更新时间：2024-01-17

- 重组人血管内皮抑素联合NP方案对人乳腺癌裸鼠移植瘤作用的实验研究
- Experimental study of recombinant human endostatin combined with NVB-Cisplatin on human breast cancer xenografts in nude mice
- 重庆医科大学学报 2011年36卷第5期页码：546-549
- 作者机构：
  
  1. 重庆医科大学附属第一医院肿瘤科
  2. 成都医学院基础医学院形态学教研室
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2011.05.018
  中图分类号： R737.9
- 纸质出版日期：2011，
扫描看全文
[1]程丽,张幸平,杨鸿捷,周涛琪,饶明月.重组人血管内皮抑素联合NP方案对人乳腺癌裸鼠移植瘤作用的实验研究[J].重庆医科大学学报,2011,36(05):546-549.

CHENG Li1, ZHANG Xing-ping1, YANG Hong-jie2, et al. Experimental study of recombinant human endostatin combined with NVB-Cisplatin on human breast cancer xenografts in nude mice[J]. Journal of Chongqing Medical University, 2011,36(5):546-549.
[1]程丽,张幸平,杨鸿捷,周涛琪,饶明月.重组人血管内皮抑素联合NP方案对人乳腺癌裸鼠移植瘤作用的实验研究[J].重庆医科大学学报,2011,36(05):546-549. DOI： 10.13406/j.cnki.cyxb.2011.05.018.

CHENG Li1, ZHANG Xing-ping1, YANG Hong-jie2, et al. Experimental study of recombinant human endostatin combined with NVB-Cisplatin on human breast cancer xenografts in nude mice[J]. Journal of Chongqing Medical University, 2011,36(5):546-549. DOI： 10.13406/j.cnki.cyxb.2011.05.018.

摘要

目的:探讨重组人血管内皮抑素（Recombinanthumanendostatin

rh-ES）联合长春瑞滨+顺铂（NP方案）化疗对人乳腺癌裸鼠移植瘤的肿瘤生长及新生血管生成的抑制作用。方法:将40只荷瘤裸鼠随机分成NP方案组（A组）、rh-ES组（B组）、联合用药组（C组）和空白对照组（D组）

每组10只。A组给予NP方案化疗1周期

B组给予rh-ES 2周期

C组给予rh-ES两周期加NP方案1周期

D组给予等剂量生理盐水。其中

rh-ES连续用药14 d为1周期

间隔7 d后重复1周期。计算各组抑瘤率

绘制肿瘤生长曲线。肿瘤组织进行免疫组化法染色

测各组血管内皮生长因子（Vascular endothelial growth factor

VEGF）及微血管密度（Microvascular density

MVD）的表达。结果:A、B、C 3组抑瘤率分别为61.80%、64.79%、88.95%

C组抑瘤率明显高于其它两组。C组与A、D两组比较VEGF表达

具有显著的统计学差异（P值均为0.001）。C组与A、B、D 3组比较MVD

P值分别为0.000

0.006和0.000

均具有统计学意义。结论:rh-ES联合NP方案化疗能明显抑制人乳腺癌裸鼠移植瘤生长及新生血管生成

且两者联用具有协同作用。

Abstract

Objective:To evaluate the inhibitory effect of recombinant human endostatin(rh-ES) combined with NP treatment on tumor growth and antiagiogenesis in nude mice after xenograft of MCF-7 cell line.Methods:40 nude mice models with human breast carcinoma were divided into group NVB-Cisplatin(group A)

group rh-ES(group B)

group NVB-Cisplatin + rh-ES(group C)and control group(group D)

each group had 10 nude mice.Group A was given NP treatment one cycle.Group B was given rh-Endostatin two cycles.Group C was given NP treatment one cycle combined with rh-Endostatin two cycles.Group D was given normal saline solution respectively.Rh-Endostatin was used two cycles

each cycle for 14 days

two cycles interval 7 days.Tumor inhibition rate(TIR)and growth curve of each group was calculated and plotted.The vascular endothelial growth factor(VEGF)and microvascular density(MVD)expression were detected by immunohistochemistry.Results:TIR of A

B and C groups were 61.80%

64.79% and 88.95%.The TIR of group C was obviously higher than other two groups.Compared with VEGF expression

group C was significantly lower than group A and group D(both P were 0.001).Compared with MVD

group C was significantly lower than other three groups.Conclusion:Rh-Endostatin combined NP treatment have synergistic effect

they can obviously inhibit tumor growth and angiogenesis.

关键词

乳腺癌MCF-7细胞株重组人血管内皮抑素血管内皮生长因子微血管密度

Keywords

breast cancerMCF-7 cell linerecombinant human endostatinVEGFMVD

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

小剂量紫杉醇联合重组人血管内皮抑素对乳腺癌MCF-7细胞抑制作用的实验研究

基于机器学习的病理组学特征可预测乳腺癌患者对新辅助化疗的反应

环状RNA hsa_circ_0002185对乳腺癌细胞瘤细胞活力和侵袭能力的影响及其作用机制

乳腺癌相关抗原ROR1 H-2Kd限制性CTL表位预测及初步鉴定

乳腺癌根治术后全X线照射胸壁及锁骨上区平卧位和胸骨水平位的肺剂量学比较